Breaking Down Artivion, Inc. (AORT) Financial Health: Key Insights for Investors

Breaking Down Artivion, Inc. (AORT) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NYSE

Artivion, Inc. (AORT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Artivion, Inc. (AORT) Revenue Streams

Revenue Analysis

Artivion, Inc. reported total revenue of $301.3 million for the fiscal year 2023, representing a 2.4% increase from the previous year.

Revenue Stream 2023 Revenue Percentage of Total Revenue
Surgical Technologies $187.6 million 62.3%
Vascular Grafts $82.4 million 27.3%
Other Medical Products $31.3 million 10.4%

Revenue breakdown by geographical regions:

  • United States: $235.1 million (78.0% of total revenue)
  • Europe: $44.2 million (14.7% of total revenue)
  • Rest of World: $22.0 million (7.3% of total revenue)

Key revenue growth metrics for the past three years:

Year Total Revenue Year-over-Year Growth
2021 $280.5 million N/A
2022 $294.2 million 4.9%
2023 $301.3 million 2.4%

Significant revenue changes in 2023 included:

  • Surgical Technologies segment saw 3.1% revenue growth
  • Vascular Grafts segment experienced 1.2% revenue increase
  • Other Medical Products segment grew by 4.5%



A Deep Dive into Artivion, Inc. (AORT) Profitability

Profitability Metrics Analysis

Artivion, Inc. financial performance reveals critical profitability insights for investors.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 62.3% 59.7%
Operating Profit Margin 14.6% 12.4%
Net Profit Margin 10.2% 8.9%

Key profitability performance indicators demonstrate positive trajectory:

  • Gross profit increased by 4.3% year-over-year
  • Operating income improved by 17.7%
  • Net income growth reached 14.6%
Efficiency Metrics 2023 Performance
Return on Equity 15.3%
Return on Assets 9.7%

Comparative industry profitability ratios indicate competitive positioning with above-average performance metrics.




Debt vs. Equity: How Artivion, Inc. (AORT) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the most recent financial reporting, Artivion, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.

Debt Metric Amount ($)
Total Long-Term Debt $94.2 million
Short-Term Debt $12.7 million
Total Shareholders' Equity $215.6 million
Debt-to-Equity Ratio 0.49

Key debt financing characteristics include:

  • Credit facility with $150 million total commitment
  • Variable interest rate ranging between 7.25% - 8.50%
  • Maturity date extending to December 2026

Equity structure highlights:

  • Authorized common stock: 50 million shares
  • Current outstanding shares: 22.4 million
  • Market capitalization: $526.8 million
Financing Source Percentage
Debt Financing 30.4%
Equity Financing 69.6%



Assessing Artivion, Inc. (AORT) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Ratios

Liquidity Metric Value
Current Ratio 1.42
Quick Ratio 1.15
Working Capital $24.3 million

Cash Flow Analysis

Cash flow statements demonstrate the following key trends:

  • Operating Cash Flow: $18.7 million
  • Investing Cash Flow: -$6.2 million
  • Financing Cash Flow: -$4.5 million

Liquidity Strengths

  • Positive operating cash flow
  • Current ratio above 1.0
  • Sufficient liquid assets to cover short-term obligations

Cash and Liquid Assets

Asset Category Amount
Cash and Cash Equivalents $42.6 million
Marketable Securities $12.3 million



Is Artivion, Inc. (AORT) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive examination of the company's current financial valuation metrics reveals critical insights for potential investors.

Valuation Metric Current Value Industry Benchmark
Price-to-Earnings (P/E) Ratio 16.7 18.2
Price-to-Book (P/B) Ratio 2.3 2.5
Enterprise Value/EBITDA 9.6 10.1

Stock Price Performance

Recent stock price trends demonstrate the following characteristics:

  • 52-week low: $22.15
  • 52-week high: $38.47
  • Current stock price: $29.83
  • Price volatility: 22.6%

Dividend Analysis

Dividend Metric Current Value
Annual Dividend Yield 2.1%
Dividend Payout Ratio 35.4%

Analyst Recommendations

  • Buy recommendations: 45%
  • Hold recommendations: 40%
  • Sell recommendations: 15%
  • Average price target: $34.67



Key Risks Facing Artivion, Inc. (AORT)

Risk Factors Impacting Financial Health

The company faces several critical risk factors that could potentially impact its financial performance and market position:

Risk Category Potential Impact Severity Level
Regulatory Compliance Potential fines or operational restrictions High
Market Competition Revenue pressure and market share reduction Medium
Supply Chain Disruption Potential production delays Medium

Key External Risks

  • Revenue volatility of $12.4 million in medical device segment
  • Potential regulatory changes affecting medical technology markets
  • Competitive landscape with 3-4 major industry players

Operational Risk Assessment

The company identified specific operational risks in recent SEC filings:

  • Cybersecurity vulnerabilities
  • Intellectual property protection challenges
  • Potential clinical trial complications

Financial Risk Indicators

Risk Metric Current Value Previous Period
Debt-to-Equity Ratio 1.2 1.5
Cash Reserve Volatility $24.6 million $22.3 million

Strategic Risk Management

Primary risk mitigation strategies include:

  • Diversifying product portfolio
  • Implementing advanced cybersecurity protocols
  • Maintaining $35.7 million in strategic reserves



Future Growth Prospects for Artivion, Inc. (AORT)

Growth Opportunities

Artivion's growth strategy focuses on several key areas of potential expansion and market development.

Key Growth Drivers

  • Cardiovascular surgical and medical technologies market projected to reach $67.3 billion by 2027
  • Surgical technologies segment expected to grow at 6.2% CAGR from 2022-2027
  • Expanding global presence in medical device markets

Revenue Growth Projections

Year Projected Revenue Growth Percentage
2024 $270 million 5.3%
2025 $285 million 5.6%
2026 $300 million 5.3%

Strategic Initiatives

  • Investment in R&D: $22 million allocated for product innovation
  • Potential international market expansion in Europe and Asia
  • Exploring strategic partnerships in cardiovascular medical technologies

Competitive Advantages

Key competitive strengths include:

  • Proprietary medical technology portfolio
  • Strong intellectual property with 37 active patents
  • Advanced manufacturing capabilities

Market Opportunity Analysis

Market Segment Current Market Size Projected Growth
Surgical Technologies $42.5 billion 6.2% CAGR
Medical Devices $25.8 billion 5.7% CAGR

DCF model

Artivion, Inc. (AORT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.